Related Experiment Video
Updated: Jul 1, 2025
Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray
Published on: April 25, 2014
Emergence of multidrug-resistant Pandoraea sputorum in Japan
Juri Koizumi1, Yutaka Nasu2, Yuji Hirai2
1Department of Clinical Microbiology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, Japan.
Abstract:
Pandoraea is a pathogenic bacterium naturally resistant to various antimicrobials, including colistin. Here, we report the whole-genome sequence of Pandoraea sputorum, which exhibits high-level multidrug resistance, isolated from a hospitalized patient in Japan.
Insights
Pandoraea sputorum is a multidrug-resistant bacterium. Whole-genome sequencing reveals its genetic basis for resistance to antimicrobials like colistin.
Area of Science:
- Microbiology
- Genomics
- Infectious Diseases
Background:
- Pandoraea species are known human pathogens.
- Natural resistance to antimicrobials, including colistin, is a concern.
- The increasing threat of antimicrobial resistance necessitates detailed genomic studies.
Purpose of the Study:
- To perform whole-genome sequencing of Pandoraea sputorum.
- To identify genetic determinants of multidrug resistance in this isolate.
- To understand the genomic basis of colistin resistance in Pandoraea.
Main Methods:
- Whole-genome sequencing using next-generation sequencing technology.
- Bioinformatic analysis for genome assembly and annotation.
- Comparative genomics to identify resistance genes.
Main Results:
- The complete genome sequence of Pandoraea sputorum was determined.
- High-level multidrug resistance, including to colistin, was confirmed.
- Specific genes and mutations associated with antimicrobial resistance were identified.
Conclusions:
- The whole-genome sequence provides a valuable resource for understanding Pandoraea pathogenesis.
- Genomic insights can guide the development of targeted therapies against multidrug-resistant Pandoraea.
- This study highlights the importance of genomic surveillance for emerging resistant pathogens.
